JP2021529559A5 - - Google Patents

Info

Publication number
JP2021529559A5
JP2021529559A5 JP2021522932A JP2021522932A JP2021529559A5 JP 2021529559 A5 JP2021529559 A5 JP 2021529559A5 JP 2021522932 A JP2021522932 A JP 2021522932A JP 2021522932 A JP2021522932 A JP 2021522932A JP 2021529559 A5 JP2021529559 A5 JP 2021529559A5
Authority
JP
Japan
Prior art keywords
immune cell
nucleotide sequence
immune
cancer
polypeptide
Prior art date
Application number
JP2021522932A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020010110A5 (https=
JP2021529559A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/040346 external-priority patent/WO2020010110A1/en
Publication of JP2021529559A publication Critical patent/JP2021529559A/ja
Publication of JPWO2020010110A5 publication Critical patent/JPWO2020010110A5/ja
Publication of JP2021529559A5 publication Critical patent/JP2021529559A5/ja
Priority to JP2024076738A priority Critical patent/JP2024102286A/ja
Pending legal-status Critical Current

Links

JP2021522932A 2018-07-03 2019-07-02 グルコース輸入を向上させるトランス代謝分子と組み合わせたキメラ受容体及びその治療的使用 Pending JP2021529559A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024076738A JP2024102286A (ja) 2018-07-03 2024-05-09 グルコース輸入を向上させるトランス代謝分子と組み合わせたキメラ受容体及びその治療的使用

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201862693677P 2018-07-03 2018-07-03
US201862693668P 2018-07-03 2018-07-03
US62/693,677 2018-07-03
US62/693,668 2018-07-03
US201862713369P 2018-08-01 2018-08-01
US62/713,369 2018-08-01
US201862756698P 2018-11-07 2018-11-07
US201862756664P 2018-11-07 2018-11-07
US62/756,698 2018-11-07
US62/756,664 2018-11-07
PCT/US2019/040346 WO2020010110A1 (en) 2018-07-03 2019-07-02 Chimeric receptors in combination with trans metabolism molecules enhancing glucose import and therapeutic uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024076738A Division JP2024102286A (ja) 2018-07-03 2024-05-09 グルコース輸入を向上させるトランス代謝分子と組み合わせたキメラ受容体及びその治療的使用

Publications (3)

Publication Number Publication Date
JP2021529559A JP2021529559A (ja) 2021-11-04
JPWO2020010110A5 JPWO2020010110A5 (https=) 2022-07-12
JP2021529559A5 true JP2021529559A5 (https=) 2022-07-12

Family

ID=69060204

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021522932A Pending JP2021529559A (ja) 2018-07-03 2019-07-02 グルコース輸入を向上させるトランス代謝分子と組み合わせたキメラ受容体及びその治療的使用
JP2024076738A Pending JP2024102286A (ja) 2018-07-03 2024-05-09 グルコース輸入を向上させるトランス代謝分子と組み合わせたキメラ受容体及びその治療的使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024076738A Pending JP2024102286A (ja) 2018-07-03 2024-05-09 グルコース輸入を向上させるトランス代謝分子と組み合わせたキメラ受容体及びその治療的使用

Country Status (8)

Country Link
EP (1) EP3817763B1 (https=)
JP (2) JP2021529559A (https=)
KR (1) KR20210030950A (https=)
CN (1) CN112638402A (https=)
AU (1) AU2019299439C1 (https=)
CA (1) CA3104862A1 (https=)
IL (1) IL279629A (https=)
WO (1) WO2020010110A1 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020028656A1 (en) 2018-08-01 2020-02-06 Nantkwest, Inc. A quadricistronic system comprising a homing receptor or a cytokine, and chimeric antigen receptor for genetic modification of immunotherapies
KR20210045418A (ko) 2018-08-14 2021-04-26 소티오, 엘엘씨 크렙스 사이클을 조정하는 트랜스 대사 분자와 조합된 키메라 항원 수용체 폴리펩타이드 및 이의 치료적 용도
EP4097219A4 (en) * 2020-01-28 2023-10-11 ImmunityBio, Inc. Chimeric antigen receptor-modified nk-92 cells targeting egfr super-family receptors
US11230699B2 (en) 2020-01-28 2022-01-25 Immunitybio, Inc. Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors
US20230248824A1 (en) * 2020-07-09 2023-08-10 The Board of Trutees of the Leland Stanford Junior University Immune cells with increased glycolytic flux
WO2022140361A1 (en) * 2020-12-22 2022-06-30 Ludwig Institute For Cancer Research Ltd Genetically engineered lymphocytes for adoptive cell therapy
US20240108652A1 (en) * 2021-02-18 2024-04-04 University Of Florida Research Foundation, Incorporated Enhancing metabolic fitness of t cells to treat cancer
WO2022226364A2 (en) * 2021-04-23 2022-10-27 Sorrento Therapeutics, Inc. Dimeric antigen receptors (dars) that bind gd2
WO2023049933A1 (en) 2021-09-27 2023-03-30 Sotio Biotech Inc. Chimeric receptor polypeptides in combination with trans metabolism molecules that re-direct glucose metabolites out of the glycolysis pathway and therapeutic uses thereof
WO2023081455A2 (en) * 2021-11-08 2023-05-11 Memorial Sloan-Kettering Cancer Center Immune cells expressing glucose transporter 5 (gluts) and compositions and methods including the same
US20250000906A1 (en) 2021-11-16 2025-01-02 Sotio Biotech Inc. Treatment of myxoid/round cell liposarcoma patients
GB202118201D0 (en) 2021-12-15 2022-01-26 King S College London Engineered immune cell
WO2023172916A2 (en) * 2022-03-08 2023-09-14 Synthekine, Inc. Orthogonal gpc3 chimeric antigen receptor t cells
CN115678856A (zh) * 2022-06-09 2023-02-03 郑州大学第一附属医院 一种肿瘤杀伤细胞及其应用
US20260053924A1 (en) 2022-08-19 2026-02-26 Sotio Biotech Inc. Genetically engineered immune cells with chimeric receptor polypeptides in combination with multiple trans metabolism molecules and therapeutic uses thereof
WO2024040207A1 (en) 2022-08-19 2024-02-22 Sotio Biotech Inc. Genetically engineered natural killer (nk) cells with chimeric receptor polypeptides in combination with trans metabolism molecules and therapeutic uses thereof
EP4694916A1 (en) 2023-04-14 2026-02-18 SOTIO Biotech Inc. Engineered immune cells for treating cancer in combination with il-2/il-15 receptor ?? agonists
WO2024215987A1 (en) 2023-04-14 2024-10-17 Sotio Biotech Inc. IMMUNE CELLS FOR TREATING CANCER IN COMBINATION WITH IL-15/IL-15Rα CONJUGATES
TW202540408A (zh) * 2024-01-09 2025-10-16 國立研究開發法人國立癌症研究中心 需要時葡萄糖攝取能力經強化之ｔ細胞、細胞集團及含有此之醫藥組成物
WO2025150522A1 (ja) * 2024-01-09 2025-07-17 国立研究開発法人国立がん研究センター サバイバーｔ細胞、サバイバーｔ細胞集団および医薬組成物
JP7685726B1 (ja) * 2024-01-09 2025-05-30 国立研究開発法人国立がん研究センター サバイバーｔ細胞、サバイバーｔ細胞集団および医薬組成物

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4650764A (en) 1983-04-12 1987-03-17 Wisconsin Alumni Research Foundation Helper cell
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US4980289A (en) 1987-04-27 1990-12-25 Wisconsin Alumni Research Foundation Promoter deficient retroviral vector
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
US5124263A (en) 1989-01-12 1992-06-23 Wisconsin Alumni Research Foundation Recombination resistant retroviral helper cell and products produced thereby
JP2752788B2 (ja) 1989-01-23 1998-05-18 カイロン コーポレイション 感染および過剰増殖障害の為の組換え療法
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
JP4041535B2 (ja) 1989-08-18 2008-01-30 オックスフォード バイオメディカ（ユーケー）リミテッド 標的細胞にベクター構造体を運搬する組換レトロウィルス
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
JP3534749B2 (ja) 1991-08-20 2004-06-07 アメリカ合衆国 アデノウイルスが介在する胃腸管への遺伝子の輸送
WO1993010218A1 (en) 1991-11-14 1993-05-27 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Vectors including foreign genes and negative selective markers
GB9125623D0 (en) 1991-12-02 1992-01-29 Dynal As Cell modification
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
EP0650370A4 (en) 1992-06-08 1995-11-22 Univ California METHODS AND COMPOSITIONS TARGETED ON SPECIFIC TISSUES.
CA2137361A1 (en) 1992-06-10 1993-12-23 W. French Anderson Vector particles resistant to inactivation by human serum
GB2269175A (en) 1992-07-31 1994-02-02 Imperial College Retroviral vectors
AU680459B2 (en) 1992-12-03 1997-07-31 Genzyme Corporation Gene therapy for cystic fibrosis
ES2249761T3 (es) 1993-06-24 2006-04-01 Advec Inc. Vectores de adenovirus para terapia genica.
CA2168202A1 (en) 1993-07-30 1995-03-16 Joseph Dougherty Efficient gene transfer into primary lymphocytes
EP1637608B1 (en) 1993-10-25 2009-07-22 CANJI, Inc. Recombinant adenoviral vector and methods of use
US5756910A (en) 1996-08-28 1998-05-26 Burgett, Inc. Method and apparatus for actuating solenoids in a player piano
ES2278399T3 (es) 1996-11-20 2007-08-01 Introgen Therapeutics, Inc. Metodo mejorado para la produccion y purificacion de vectores adenovirales.
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
EP1135495A2 (en) 1998-12-01 2001-09-26 Genentech, Inc. Secreted amd transmembrane polypeptides and nucleic acids encoding the same
US7052906B1 (en) 1999-04-16 2006-05-30 Celltech R & D Limited Synthetic transmembrane components
WO2001046418A1 (en) * 1999-12-21 2001-06-28 Zymogenetics, Inc. Human slit polypeptide zslit3
US7435596B2 (en) 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
CA2748314C (en) 2009-02-03 2018-10-02 Amunix Operating Inc. Extended recombinant polypeptides and compositions comprising same
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
WO2013040557A2 (en) 2011-09-16 2013-03-21 The Trustees Of The University Of Pennsylvania Rna engineered t cells for the treatment of cancer
EP3057986B1 (en) 2013-10-17 2017-12-27 National University of Singapore Chimeric receptor that triggers antibody-dependent cell cytotoxicity against multiple tumors
US10246505B2 (en) * 2013-11-25 2019-04-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric antigen receptors to control HIV infection
US20180133252A9 (en) 2014-09-09 2018-05-17 Unum Therapeutics Inc. Chimeric receptors and uses thereof in immune therapy
US11020429B2 (en) * 2015-11-05 2021-06-01 Juno Therapeutics, Inc. Vectors and genetically engineered immune cells expressing metabolic pathway modulators and uses in adoptive cell therapy
EP3430036A4 (en) 2016-03-18 2019-08-14 Unum Therapeutics MODIFIED CHIMERIC RECEPTORS AND USES IN IMMUNOTHERAPY
US11377637B2 (en) * 2016-04-15 2022-07-05 Memorial Sloan Kettering Cancer Center Transgenic T cell and chimeric antigen receptor T cell compositions and related methods
CN105949324B (zh) * 2016-06-30 2019-08-27 上海恒润达生生物科技有限公司 靶向gpc3的嵌合抗原受体及其用途
EP4342978A3 (en) * 2016-09-01 2024-07-03 Chimera Bioengineering Inc. Gold optimized car t-cells
EP4282969A3 (en) * 2016-09-02 2024-01-31 Lentigen Technology, Inc. Compositions and methods for treating cancer with duocars
EP3523331A1 (en) * 2016-10-07 2019-08-14 Novartis AG Chimeric antigen receptors for the treatment of cancer
AU2019336229A1 (en) * 2018-09-07 2021-03-18 Sotio, LLC Chimeric receptor polypeptides in combination with trans metabolism molecules modulating intracellular lactate concentrations and therapeutic uses thereof

Similar Documents

Publication Publication Date Title
JP2021529559A5 (https=)
JP2021536265A5 (https=)
JP2021534740A5 (https=)
US12410248B2 (en) Chimeric antigen receptor and its use
JPWO2020010110A5 (https=)
JP7490915B2 (ja) 抗メソテリンキメラ抗原受容体（ｃａｒ）構築物及びその使用
US20190023764A1 (en) Car having replicated binding motifs in a co-stimulatory domain
JP7175769B2 (ja) 改善された養子ｔ細胞療法
US12076378B2 (en) Use of car and bite technology coupled with an SCFV from an antibody against human thymidine kinase 1 to specifically target tumors
CN109053899B (zh) 一种含人转铁蛋白抗原表位序列的嵌合体抗原受体
JP2024023228A5 (https=)
RU2018118817A (ru) Химерные рецепторы антигена, нацеленные на her2
EP2709671A1 (en) Method
CN109280086B (zh) 一种肿瘤微环境特异性活化的缺氧诱导型嵌合抗原受体
JPWO2020051493A5 (https=)
US20220298223A1 (en) B CELL TARGETED PARALLEL CAR (pCAR) THERAPEUTIC AGENTS
WO2018045034A1 (en) Chimeric antigen receptors having gitr intracellular domain as co-stimulatory domain
EP3098237A1 (en) Anti-toso chimeric antigen receptor and its use
WO2019115818A2 (en) Pooling signaling and costimulatory domains in flexible car design
Vyas et al. Mono-and dual-targeting triplebodies activate natural killer cells and have anti-tumor activity in vitro and in vivo against chronic lymphocytic leukemia
JPWO2020037066A5 (https=)
EP4210733B1 (en) System for inducible expression of an adapter in immune cells
JPWO2023044456A5 (https=)
CN119301157A (zh) 用于癌症治疗的抗活化的Trop-2的嵌合抗原受体构建体
JPWO2023049933A5 (https=)